{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:34:59Z","timestamp":1793745299687,"version":"4.6.1"},"reference-count":63,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Although chimeric antigen receptor (CAR) T-cell therapy provides a potential cure for patients with non-Hodgkin B-cell lymphomas\/leukemias and plasma cell myelomas, rare reports of the development of T-cell lymphomas (TCLs) in these patients have raised serious safety concerns regarding whether CAR T-cell therapy could directly contribute to the development of TCLs in a specific patient or in patients with certain types of underlying hematologic malignancies. This review aims to comprehensively evaluate the clinicodemographic features, types of TCLs, immunophenotypic characteristics, mutational profiles, and CAR T-cell transgene expression status within the lymphoma cells, as well as explore the underlying mechanisms of lymphomagenesis. A special focus is placed on the interplay between preexisting clonal hematopoiesis, immune dysregulation, and reported genomic alterations that may predispose to and\/or drive T-cell lymphomagenesis. Among the total 18 reported cases, TCLs developed in patients with all types of underlying hematologic malignancies and occurred after treatment with all types of widely used commercial CAR T-cell products. Most TCLs showed aberrant T-cell phenotypes according to CD4 and\/or CD8 expression. The infused CAR T-cell transgene in lymphoma cells was detected in 63% (10\/16) of cases, and 73% (8\/11) of cases showed the integration of the CAR transgene into a known tumor suppressor gene or oncogene. At the molecular genomic level, mutations involved in epigenetic regulators (TET2 and DNMT3A) and JAK-STAT signaling pathway, especially JAK3 mutation, were often detected. The potential mechanisms of T-cell lymphomagenesis were complex and multifactorial, including but not limited to preexisting clonal hematopoiesis of indeterminate potential, malignant transformation of CAR T cells, and lymphodepletion chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026021166","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:58:53Z","timestamp":1787259533000},"page":"6981-6990","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["A comprehensive review of T-cell lymphoma following CAR T-cell immunotherapy"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-9535","authenticated-orcid":false,"given":"Wangpan Jackson","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-8963","authenticated-orcid":false,"given":"Huan-You","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"17","key":"2026102711121505200_bib1","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.3390\/cancers17172796","article-title":"CD19 CAR-T outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma: a retrospective cohort study from the Calabria Referral Center in Southern Italy","volume":"17","author":"Caracciolo","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026102711121505200_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20411\/pai.v9i1.647","article-title":"Chimeric antigen receptor (CAR)-T cell therapy for non-Hodgkin's lymphoma","volume":"9","author":"Giraudo","year":"2024","journal-title":"Pathog Immun"},{"issue":"5","key":"2026102711121505200_bib3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"2026102711121505200_bib4","doi-asserted-by":"crossref","first-page":"e2024010","DOI":"10.4084\/MJHID.2024.010","article-title":"CAR-T cell therapy in B-cell acute lymphoblastic leukemia","volume":"16","author":"Testa","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"2026102711121505200_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.beha.2018.04.001","article-title":"CAR T cell therapy for B-cell lymphomas","volume":"31","author":"Chavez","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2026102711121505200_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026102711121505200_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"4","key":"2026102711121505200_bib8","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026102711121505200_bib9","doi-asserted-by":"crossref","first-page":"879608","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"2026102711121505200_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/hematology.2024000534","article-title":"Late complications and long-term care of adult CAR T-cell patients","volume":"2024","author":"Bishop","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2026102711121505200_bib11","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T-cell lymphomas after CAR T-cell therapy","volume":"39","author":"Braun","year":"2025","journal-title":"Leukemia"},{"issue":"4","key":"2026102711121505200_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2026102711121505200_bib13","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR T cell therapy in the DESCAR-T registry","volume":"31","author":"Dulery","year":"2025","journal-title":"Nat Med"},{"key":"2026102711121505200_bib14","unstructured":"US Food and Drug Administration\n          . FDA requires boxed warning for T-cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T-cell immunotherapies. 2024. Accessed 11 July 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed."},{"key":"2026102711121505200_bib15","doi-asserted-by":"crossref","first-page":"102684","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"20","key":"2026102711121505200_bib16","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026102711121505200_bib17","doi-asserted-by":"crossref","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Goyco Vera","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"2026102711121505200_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","article-title":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","volume":"22","author":"Braendstrup","year":"2020","journal-title":"Cytotherapy"},{"key":"2026102711121505200_bib19","unstructured":"National Comprehensive Cancer Network\n          . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Management of CAR T-cell and lymphocyte engager-related toxicities. Version 1.2025. 2025. Accessed 11 July 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cellular_tox.pdf."},{"issue":"1","key":"2026102711121505200_bib20","doi-asserted-by":"crossref","first-page":"e2025039","DOI":"10.4084\/MJHID.2025.039","article-title":"Toxicities associated with CAR-T cell therapies","volume":"17","author":"Testa","year":"2025","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"2026102711121505200_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"16","key":"2026102711121505200_bib22","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"224","key":"2026102711121505200_bib23","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"3","key":"2026102711121505200_bib24","first-page":"222","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026102711121505200_bib25","doi-asserted-by":"crossref","first-page":"e2461683","DOI":"10.1001\/jamanetworkopen.2024.61683","article-title":"Late adverse events after chimeric antigen receptor T-cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma","volume":"8","author":"Camacho-Arteaga","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2026102711121505200_bib26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"2026102711121505200_bib27","unstructured":"Legend Biotech\n          . Legend Biotech announces US FDA label update for CARVYKTI (ciltacabtagene autoleucel; cilta-cel). 2024. Accessed 11 July 2026. https:\/\/investors.legendbiotech.com\/news-releases\/news-release-details\/legend-biotechs-carvyktir-ciltacabtagene-autoleucel-becomes."},{"issue":"4","key":"2026102711121505200_bib28","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/bjh.19590","article-title":"Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: a report from the Italian CART-SIE study","volume":"205","author":"Barone","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"2026102711121505200_bib29","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jamaoncol.2023.7182","article-title":"Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy","volume":"10","author":"Gurney","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"2026102711121505200_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3857\/roj.2018.00290","article-title":"Radiation induced secondary malignancies: a review article","volume":"36","author":"Dracham","year":"2018","journal-title":"Radiat Oncol J"},{"issue":"6","key":"2026102711121505200_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00129804-200311000-00004","article-title":"Chemotherapy-induced secondary malignancies","volume":"26","author":"Vega-Stromberg","year":"2003","journal-title":"J Infus Nurs"},{"issue":"7","key":"2026102711121505200_bib32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"2026102711121505200_bib33","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2024025828","article-title":"T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities","volume":"144","author":"Hu","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026102711121505200_bib34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41434-025-00586-x","article-title":"Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected cases","volume":"33","author":"Berg","year":"2026","journal-title":"Gene Ther"},{"issue":"2","key":"2026102711121505200_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaoncol.2024.5412","article-title":"Second primary cancer after chimeric antigen receptor-T-cell therapy: a review","volume":"11","author":"Patel","year":"2025","journal-title":"JAMA Oncol"},{"issue":"13","key":"2026102711121505200_bib36","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","article-title":"Aggressive lymphoma after CD19 CAR T-cell therapy","volume":"391","author":"Kobbe","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"2026102711121505200_bib37","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.3390\/ijms26178388","article-title":"Lymphoid and myeloid proliferations after chimeric antigen receptor (CAR) T-cell therapy: the pathologist's perspective","volume":"26","author":"Zhou","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026102711121505200_bib38","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1038\/s41467-025-62709-7","article-title":"A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy","volume":"16","author":"Maurer","year":"2025","journal-title":"Nat Commun"},{"issue":"22","key":"2026102711121505200_bib39","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"2026102711121505200_bib40","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"2026102711121505200_bib41","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"2026102711121505200_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"2026102711121505200_bib43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","article-title":"Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody","volume":"31","author":"Braun","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"2026102711121505200_bib44","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12185-025-04074-1","article-title":"Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy","volume":"122","author":"Tatetsu","year":"2025","journal-title":"Int J Hematol"},{"issue":"9","key":"2026102711121505200_bib45","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJMc2408733","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"391","author":"Godfrey","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026102711121505200_bib46","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","article-title":"Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies","volume":"31","author":"Jadlowsky","year":"2025","journal-title":"Nat Med"},{"issue":"16","key":"2026102711121505200_bib47","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2026102711121505200_bib48","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2026102711121505200_bib49","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood.2025031423","article-title":"Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine","volume":"147","author":"Hosoya","year":"2026","journal-title":"Blood"},{"key":"2026102711121505200_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2443965","article-title":"T-cell malignancies following CAR T-cell therapy: insights from the FDA Adverse Event Reporting System (FAERS)","volume":"22","author":"Di Napoli","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"22","key":"2026102711121505200_bib51","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2013-07-512830","article-title":"Indolent T-cell lymphoproliferative disease of the gastrointestinal tract","volume":"122","author":"Perry","year":"2013","journal-title":"Blood"},{"key":"2026102711121505200_bib52","volume-title":"WHO Classification of Tumours: Haematolymphoid Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2024","edition":"5th ed"},{"issue":"12","key":"2026102711121505200_bib53","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2026102711121505200_bib54","doi-asserted-by":"crossref","first-page":"102028","DOI":"10.1016\/j.labinv.2024.102028","article-title":"Indolent T-cell\/natural killer-cell lymphomas \/ lymphoproliferative disorders of the gastrointestinal tract-what have we learned in the last decade?","volume":"104","author":"Wang","year":"2024","journal-title":"Lab Invest"},{"issue":"12","key":"2026102711121505200_bib55","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2026102711121505200_bib56","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3324\/haematol.2019.230961","article-title":"Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract","volume":"105","author":"Soderquist","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2026102711121505200_bib57","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of JAK\/STAT inhibition by SOCS1","volume":"9","author":"Liau","year":"2018","journal-title":"Nat Commun"},{"key":"2026102711121505200_bib58","doi-asserted-by":"crossref","first-page":"101048","DOI":"10.1016\/j.neo.2024.101048","article-title":"Clinical and genetic profile of Chinese patients with indolent natural killer-cell lymphoproliferative disorder of the gastrointestinal tract","volume":"57","author":"Chen","year":"2024","journal-title":"Neoplasia"},{"issue":"suppl 1","key":"2026102711121505200_bib59","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2024-204188","article-title":"Expanding the role of SH2B3: T cell large granular lymphocytosis (LGL) and common variable immune deficiency in the setting of biallelic SH2B3 mutations","volume":"144","author":"Hangse","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2026102711121505200_bib60","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"2026102711121505200_bib61","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"2026102711121505200_bib62","doi-asserted-by":"crossref","first-page":"e70047","DOI":"10.1002\/jha2.70047","article-title":"Treatment of an indolent T-cell lymphoma of the gastrointestinal tract harboring STAT3::JAK2 with jakafi (ruxolitinib) with significant clinical improvements","volume":"6","author":"Cao","year":"2025","journal-title":"EJHaem"},{"key":"2026102711121505200_bib63","doi-asserted-by":"crossref","first-page":"1332878","DOI":"10.3389\/fmolb.2024.1332878","article-title":"Ssu72: a versatile protein with functions in transcription and beyond","volume":"11","author":"Fidler","year":"2024","journal-title":"Front Mol Biosci"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6981\/2595268\/blooda_adv-2026-021166-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6981\/2595268\/blooda_adv-2026-021166-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:12:33Z","timestamp":1793113953000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/6981\/570340\/A-comprehensive-review-of-T-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":63,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021166","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,15]]}}}